Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

被引：29

作者：

Davies, Faith E. ^{[1
]}

Pawlyn, Charlotte ^{[2
,3
]}

Usmani, Saad Z. ^{[4
]}

San-Miguel, Jesus F. ^{[5
]}

Einsele, Hermann ^{[6
]}

Boyle, Eileen M. ^{[1
]}

Corre, Jill ^{[7
,8
]}

Auclair, Daniel ^{[9
]}

Cho, Hearn Jay ^{[9
,10
]}

Lonial, Sagar ^{[11
]}

Sonneveld, Pieter ^{[12
]}

Stewart, A. Keith ^{[13
,14
]}

Bergsagel, P. Leif ^{[15
]}

Kaiser, Martin F. ^{[3
,16
]}

Weisel, Katja ^{[17
]}

Keats, Jonathan J. ^{[18
]}

Mikhael, Joseph R. ^{[19
]}

Morgan, Kathryn E. ^{[20
]}

Ghobrial, Irene M. ^{[21
]}

Orlowski, Robert Z. ^{[22
]}

Landgren, C. Ola ^{[23
]}

Gay, Francesca ^{[24
]}

Caers, Joseph ^{[25
]}

Chng, Wee Joo ^{[26
,27
,28
,29
]}

Chari, Ajai ^{[10
]}

Walker, Brian A. ^{[30
]}

Kumar, Shaji K. ^{[31
]}

Costa, Luciano J. ^{[32
]}

Anderson, Kenneth C. ^{[21
]}

Morgan, Gareth J. ^{[1
]}

机构：

[1] NYU Langone, Perlmutter Canc Ctr, New York, NY USA

[2] Inst Canc Res, Div Canc Therapeut, London, England

[3] Royal Marsden Hosp, Dept Haematol, London, England

[4] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA

[5] Clin Univ Navarra, CIBERONC, IDISNA, CIMA, Pamplona, Spain

[6] Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany

[7] Inst Univ Canc, Unite Genom Myelome, Toulouse, France

[8] Inst Natl Sante & Rech Med, Paris, France

[9] Multiple Myeloma Res Fdn, Norwalk, CT USA

[10] Icahn Sch Med Mt Sinai, Multiple Myeloma Ctr Excellence, New York, NY 10029 USA

[11] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

[12] Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[13] Univ Hlth Network, Toronto, ON, Canada

[14] Princess Margaret Canc Ctr, Toronto, ON, Canada

[15] Mayo Clin, Dept Med, Phoenix, AZ USA

[16] Inst Canc Res, Div Genet & Epidemiol, London, England

[17] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany

[18] Translat Genom Res Inst, Integrated Canc Genom, Phoenix, AZ USA

[19] City Hope Canc Ctr, Translat Genom Res Inst, Phoenix, AZ USA

[20] Myeloma Patients Europe, Brussels, Belgium

[21] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[22] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[23] Univ Miami, Sylvester Comprehens Canc Ctr, Myeloma Program, Miami, FL USA

[24] Univ Torino, Div Hematol, Turin, Italy

[25] Ctr Hosp Univ CHU Liege, Dept Hematol, Liege, Belgium

[26] Natl Univ Canc Inst, Singapore, Singapore

[27] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore

[28] Natl Univ Singapore, NUS Ctr Canc Res, Yong Loo Lin Sch Med, Singapore, Singapore

[29] Natl Univ Singapore, Dept Med, Yong Loo Lin Sch Med, Singapore, Singapore

[30] Indiana Univ, Melvin & Bren Simon Comprehens Canc Ctr, Div Hematol Oncol, Indianapolis, IN USA

[31] Mayo Clin, Dept Hematol, Rochester, MN USA

[32] Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, Birmingham, AL 35294 USA

来源：

BLOOD CANCER DISCOVERY | 2022年 / 3卷 / 07期

关键词：

STEM-CELL TRANSPLANTATION; INTERNATIONAL STAGING SYSTEM; MINIMAL RESIDUAL DISEASE; TERM-FOLLOW-UP; LENALIDOMIDE MAINTENANCE; PLUS BORTEZOMIB; GENE-EXPRESSION; DOUBLE-BLIND; DEXAMETHASONE; THERAPY;

D O I：

10.1158/2643-3230.BCD-21-0205

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continu-ing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.

引用

页码：273 / 284

页数：12

共 108 条

[1] Targeting the BRAF V600E Mutation in Multiple Myeloma
Andrulis, Mindaugas
Lehners, Nicola
Capper, David
Penzel, Roland
Heining, Christoph
Huellein, Jennifer
Zenz, Thorsten
von Deimling, Andreas
Schirmacher, Peter
Ho, Anthony D.
Goldschmidt, Hartmut
Neben, Kai
Raab, Marc S.
[J]. CANCER DISCOVERY, 2013, 3 (08) : 862 - 869
[2] Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, Michel
Lauwers-Cances, Valerie
Hulin, Cyrille
Leleu, Xavier
Caillot, Denis
Escoffre, Martine
Arnulf, Bertrand
Macro, Margaret
Belhadj, Karim
Garderet, Laurent
Roussel, Murielle
Payen, Catherine
Mathiot, Claire
Fermand, Jean P.
Meuleman, Nathalie
Rollet, Sandrine
Maglio, Michelle E.
Zeytoonjian, Andrea A.
Weller, Edie A.
Munshi, Nikhil
Anderson, Kenneth C.
Richardson, Paul G.
Facon, Thierry
Avet-Loiseau, Herve
Harousseau, Jean-Luc
Moreau, Philippe
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14) : 1311 - 1320
[3] Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival
Avet-Loiseau, Herve
Attal, Michel
Campion, Loic
Caillot, Denis
Hulin, Cyrille
Marit, Gerald
Stoppa, Anne-Marie
Voillat, Laurent
Wetterwald, Marc
Pegourie, Brigitte
Voog, Eric
Tiab, Mourad
Banos, Anne
Jaubert, Jerome
Bouscary, Didier
Macro, Margaret
Kolb, Brigitte
Traulle, Catherine
Mathiot, Claire
Magrangeas, Florence
Minvielle, Stephane
Facon, Thierry
Moreau, Philippe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1949 - 1952
[4] Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, Lotfi
Dimopoulos, Meletios A.
Dispenzieri, Angela
Catalano, John
Belch, Andrew R.
Cavo, Michele
Pinto, Antonello
Weisel, Katja
Ludwig, Heinz
Bahlis, Nizar
Banos, Anne
Tiab, Mourad
Delforge, Michel
Cavenagh, Jamie
Geraldes, Catarina
Lee, Je-Jung
Chen, Christine
Oriol, Albert
de la Rubia, Javier
Qiu, Lugui
White, Darrell J.
Binder, Daniel
Anderson, Kenneth
Fermand, Jean-Paul
Moreau, Philippe
Attal, Michel
Knight, Robert
Chen, Guang
Van Oostendorp, Jason
Jacques, Christian
Ervin-Haynes, Annette
Avet-Loiseau, Herve
Hulin, Cyrille
Facon, Thierry
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (10) : 906 - 917
[5] Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
Bergsagel, PL
Kuehl, WM
Zhan, FH
Sawyer, J
Barlogie, B
Shaughnessy, J
[J]. BLOOD, 2005, 106 (01) : 296 - 303
[6] Extramedullary multiple myeloma
Bhutani, Manisha
Foureau, David M.
Atrash, Shebli
Voorhees, Peter M.
Usmani, Saad Z.
[J]. LEUKEMIA, 2020, 34 (01) : 1 - 20
[7] A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma
Bolli, N.
Li, Y.
Sathiaseelan, V.
Raine, K.
Jones, D.
Ganly, P.
Cocito, F.
Bignell, G.
Chapman, M. A.
Sperling, A. S.
Anderson, K. C.
Avet-Loiseau, H.
Minvielle, S.
Campbell, P. J.
Munshi, N. C.
[J]. BLOOD CANCER JOURNAL, 2016, 6 : e467 - e467
[8] Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Bolli, Niccolo
Avet-Loiseau, Herve
Wedge, David C.
Van Loo, Peter
Alexandrov, Ludmil B.
Martincorena, Inigo
Dawson, Kevin J.
Iorio, Francesco
Nik-Zainal, Serena
Bignell, Graham R.
Hinton, Jonathan W.
Li, Yilong
Tubio, Jose M. C.
McLaren, Stuart
Meara, Sarah O'
Butler, Adam P.
Teague, Jon W.
Mudie, Laura
Anderson, Elizabeth
Rashid, Naim
Tai, Yu-Tzu
Shammas, Masood A.
Sperling, Adam S.
Fulciniti, Mariateresa
Richardson, Paul G.
Parmigiani, Giovanni
Magrangeas, Florence
Minvielle, Stephane
Moreau, Philippe
Attal, Michel
Facon, Thierry
Futreal, P. Andrew
Anderson, Kenneth C.
Campbell, Peter J.
Munshi, Nikhil C.
[J]. NATURE COMMUNICATIONS, 2014, 5
[9] A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
Boyd, K. D.
Ross, F. M.
Chiecchio, L.
Dagrada, G. P.
Konn, Z. J.
Tapper, W. J.
Walker, B. A.
Wardell, C. P.
Gregory, W. M.
Szubert, A. J.
Bell, S. E.
Child, J. A.
Jackson, G. H.
Davies, F. E.
Morgan, G. J.
[J]. LEUKEMIA, 2012, 26 (02) : 349 - 355
[10] High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse
Boyle, Eileen M.
Rosenthal, Adam
Wang, Yan
Farmer, Philip
Rutherford, Michael
Ashby, Cody
Bauer, Michael
Johnson, Sarah K.
Wardell, Christopher P.
Hoering, Antje
Schinke, Carolina
Thanendrarajan, Sharmilan
Zangari, Maurizio
Barlogie, Bart
Davies, Faith E.
Walker, Brian A.
van Rhee, Frits
Morgan, Gareth J.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 195 (02) : 283 - 286

← 1 2 3 4 5 6 7 8 9 10 →